With more elucidation of disease pathology, the development of next generation protein therapeutics has become the trend of protein therapeutics development. Unfortunately, these next-generation biologics (NGBs), such as fusion proteins, exhibit additional levels of complexity beyond regular monoclonal antibody therapeutics. New methods, techniques and efficient data analysis software in liquid chromatography-tandem mass spectrometry (LC-MS/MS) hold the key for accelerating the development of NGBs and increasing their availability.
Attend this webinar to:
- Discover how protein impurity in intact mass analysis can be easily identified with Biologics Explorer with its powerful visualization tool
- Learn about the novel capabilities of the SCIEX ZenoTOF 7600 System with a patented ion trap and how it can be applied to the acquisition of intact mass and peptide-level data
- Explore how to perform intact mass analysis for heavily glycosylated proteins
- Learn how to get accurate site-specific N-linked and O-linked glycan profiling